Sex Differences in Use of Psychotropic Drugs and Drug-Induced Side Effects in Schizophrenia Patients: Findings of the Research on Asia Psychotropic Prescription (REAP) Studies

Objective: The aim of this study was to investigate the sex differences in prescribing patterns of psychotropic drugs and drug-induced side effects in schizophrenia patients in Asia using the data of the Research on Asian Psychotropic Prescription Pattern (REAP) surveys. Method: The prescription patterns of 6,441 schizophrenia inpatients in six Asian countries and regions were investigated during the 2001–2009 period. The patients' socio-demographic and clinical characteristics and their prescriptions for psychotropic drugs were recorded using a standardized protocol and data collection procedure. Results: Univariate analyses found the following factors to be significantly associated with the male sex: a younger age, higher doses of antipsychotics, less prominent delusions and hallucinations, more prominent negative symptoms, less likelihood of a prescription for second-generation antipsychotics (SGAs), greater use of antipsychotic polypharmacy, mood stabilizers and depot antipsychotics, more frequent tardive dyskinesia (TD), and less weight gain. In multivariate analyses, fewer prescriptions for SGAs, greater use of mood stabilizers, anticholinergics, antipsychotic polypharmacy and depot antipsychotics, extrapyramidal side effects (EPS) and TD, and less weight gain were independently associated with the male sex. Conclusions: Sex is one of the independent contributors to psychotropic prescription and side effects in Asian schizophrenia patients. Psychopharmacological treatment guidelines for schizophrenia should consider the sexes separately.

[1]  Qijing Bo,et al.  Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. , 2010, The American journal of psychiatry.

[2]  Qijing Bo,et al.  Sex differences in patients with schizophrenia: A prospective, multi-center study , 2010, Psychiatry Research.

[3]  W. Tang,et al.  Gender Differences in Sociodemographic and Clinical Characteristic and the Quality of Life of Chinese Schizophrenia Patients , 2010, The Australian and New Zealand journal of psychiatry.

[4]  A. Meyer-Lindenberg,et al.  Polypharmacy in schizophrenia , 2010, Current opinion in psychiatry.

[5]  S. Kapur,et al.  The Maudsley Prescribing Guidelines , 2009 .

[6]  P. Parzer,et al.  Do sex differences affect prefrontal cortex associated cognition in schizophrenia? , 2009, Schizophrenia Research.

[7]  K. Sim,et al.  Psychotropic prescription practices in east Asia: looking back and peering ahead , 2008, Current opinion in psychiatry.

[8]  W. Tang,et al.  Long-Term Use of Mood Stabilizers and Its Impact on the Quality of Life of Chinese Patients With Schizophrenia , 2008, Clinical neuropharmacology.

[9]  F. Limosin,et al.  Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia , 2008, Acta psychiatrica Scandinavica.

[10]  G. Ungvari,et al.  Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. , 2008, International journal of clinical pharmacology and therapeutics.

[11]  Young-Min Park,et al.  Possible association between the −2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  N. Shinfuku,et al.  Pharmacotherapy for schizophrenic inpatients in East Asia – Changes and challenges , 2008, International review of psychiatry.

[13]  W. K. Kennedy,et al.  The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia , 2007, Current medical research and opinion.

[14]  G. Kaprinis,et al.  Beneficial effect of long-acting injectable risperidone on the neurocognitive deficit of a schizophrenic patient: A case report. , 2006, International journal of clinical pharmacology and therapeutics.

[15]  Ana Cristina Chaves,et al.  Sex Selection Bias in Schizophrenia Antipsychotic Trials , 2006, Journal of clinical psychopharmacology.

[16]  Young-Min Park,et al.  Weight gain associated with the α2a‐adrenergic receptor −1291 C/G polymorphism and olanzapine treatment , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[17]  A. Schene,et al.  Sex Differences in the Subjective Tolerability of Antipsychotic Drugs , 2005, Journal of clinical psychopharmacology.

[18]  M. Seeman,et al.  Gender differences in the prescribing of antipsychotic drugs. , 2004, The American journal of psychiatry.

[19]  T. Si,et al.  Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change , 2004, Psychiatry and clinical neurosciences.

[20]  S. Woods,et al.  Chlorpromazine equivalent doses for the newer atypical antipsychotics. , 2003, The Journal of clinical psychiatry.

[21]  H. Häfner.  Gender differences in schizophrenia , 2003, Psychoneuroendocrinology.

[22]  L. Kahn,et al.  Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects , 2003, Psychoneuroendocrinology.

[23]  P. Houck,et al.  Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. , 2002, Clinical therapeutics.

[24]  D. Allison,et al.  Changes in body mass index for individuals with and without schizophrenia, 1987–1996 , 2002, Schizophrenia Research.

[25]  M. Tohen,et al.  Sex differences in clinical response to olanzapine compared with haloperidol , 2002, Psychiatry Research.

[26]  J. Usall,et al.  Gender differences in a sample of schizophrenic outpatients. , 2001, Comprehensive psychiatry.

[27]  M. Miller.  Gender-Based Differences in the Toxicity of Pharmaceuticals—The Food and Drug Administration's Perspective , 2001, International journal of toxicology.

[28]  K. Melkersson,et al.  Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. , 2001, British journal of clinical pharmacology.

[29]  D. Wirshing.  Adverse effects of atypical antipsychotics. , 2001, The Journal of clinical psychiatry.

[30]  A. Riecher-Rössler,et al.  Gender aspects in schizophrenia: bridging the border between social and biological psychiatry , 2000, Acta psychiatrica Scandinavica. Supplementum.

[31]  A. Torgalsbøen.  Full recovery from schizophrenia: the prognostic role of premorbid adjustment, symptoms at first admission, precipitating events and gender , 1999, Psychiatry Research.

[32]  T. Baptista.  Body weight gain induced by antipsychotic drugs: mechanisms and management , 1999, Acta psychiatrica Scandinavica.

[33]  J. Guelfi,et al.  Guidelines for depot antipsychotic treatment in schizophrenia , 1998, European Neuropsychopharmacology.

[34]  S. Cole,et al.  Is the earlier age at onset of schizophrenia in males a confounded finding? , 1996, Schizophrenia Research.

[35]  R. Conley,et al.  Patient response and resource management: another view of clozapine treatment of schizophrenia. , 1995, The American journal of psychiatry.

[36]  J. Lieberman,et al.  Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. , 1995, The American journal of psychiatry.

[37]  L. Citrome.  Use of Lithium, Carbamazepine, and Valproic Acid in a State-Operated Psychiatric Hospital , 1995, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[38]  V. Peralta,et al.  Neuroleptic dose and schizophrenic symptoms , 1994, Acta psychiatrica Scandinavica.

[39]  W. Glazer,et al.  Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.

[40]  Daniel E. Casey,et al.  Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia , 1991, Schizophrenia Research.

[41]  M. Reveley,et al.  Schizophrenia with Good and Poor Outcome. I: Early Clinical Features, Response to Neuroleptics and Signs of Organic Dysfunction , 1985, British Journal of Psychiatry.

[42]  E. Mundo,et al.  Intramuscular Preparations of Antipsychotics , 2012, Drugs.

[43]  M. Pompili,et al.  Sex and ethnic differences among South Tirolean suicides: A psychological autopsy study , 2009, European Psychiatry.

[44]  T. Si,et al.  High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. , 2009, British journal of clinical pharmacology.

[45]  Wu Zhi-jian.  A study of additive effect of sodium-valproate in the treatment of schizophrenia , 2004 .

[46]  E. Mundo,et al.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. , 2003, Drugs.

[47]  M. Anthony,et al.  Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. , 2002, Journal of women's health & gender-based medicine.

[48]  J. Meyer,et al.  Effects of atypical antipsychotics on weight and serum lipid levels. , 2001, The Journal of clinical psychiatry.

[49]  J. Guelfi,et al.  Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. , 1998, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[50]  H. Meltzer,et al.  Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. , 1997, The American journal of psychiatry.

[51]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[52]  Bruce G. Link,et al.  Gender and the expression of schizophrenia. , 1988, Journal of psychiatric research.